
Record growth masks rising execution risk — Xanthine guidance cut signals caution
Xanthine guidance cut · CDMO growth · working capital strain
BSE: 543748
P/L Snapshot
Q2 FY27 · standalone
Shareholding
Pattern breakdown
P/L Trends
(in crores)

Xanthine guidance cut · CDMO growth · working capital strain

Xanthine price normalization · CDMO 40-50% growth · Capex ₹350-400 Cr

API expansion · margin momentum · stamp duty headwind
Corporate Events
Board Meeting
The meeting of the Board of Directors is scheduled to consid…
BSE Filing ↗Board Meeting
The Company has also initiated sending letters containing th…
BSE Filing ↗Board Meeting
The meeting of the Board of Directors is scheduled to consid…
BSE Filing ↗Board Meeting
The Board Meeting was held on May 25, 2026. The agenda incl…
BSE Filing ↗Board Meeting
Consider and approve Audited Financial Results for the quart…
BSE Filing ↗Board Meeting
Consider and approve Audited Financial Results for the quart…
BSE Filing ↗Board Meeting
Consider and approve Audited Financial Results for the quart…
BSE Filing ↗